參 考 文 獻

(1) Barza M. Scheife RT. Drug therapy reviews: Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics--part 4: aminoglycosides. American Journal of Hospital Pharmacy. 34(7): 723-37, 1977.

(2) Schiffman DO. Evaluation of amikacin sulfate (Amikin). A new aminoglycoside antibiotic. JAMA. 238(14): 1547-50, 1977.

(3) Florey, K., "Analytical Profiles of Drug Substances", Academic Press, New York, vol. 12, p.38, 1983.

(4) Gunawardana G. Childress C. Tripp M. Zhang X. West P. The identification of 1,6'- and 1,3"-di-N-(L-4-amino-2-hydroxybutyryl) derivatives of kanamycin as synthetic byproducts of amikacin. Journal of Antibiotics. 50(10): 887-9, 1997.

(5) Naito T. Nakagawa S. Abe Y. Toda S. Fujisawa K. Aminoglycoside antibiotics. II. Configurational and positional isomers of BB-K8. Journal of Antibiotics. 26(5): 297-301, 1973.

(6) Kawaguchi H. Naito T. Nakagawa S. Fujisawa KI. BB-K 8, a new semisynthetic aminoglycoside antibiotic. Journal of Antibiotics. 25(12): 695-708, 1972.

(7)Isogai K. Shimizu Y. Kawada Y. Nishiura T. [Laboratory and clinical studies on amikacin (BB-K8), a new semisynthetic aminoglycoside (author's transl)]. [Japanese] Japanese Journal of Antibiotics. 27(3):328-36, 1974.

(8) Naito T. Nakagawa S. Narita Y. Toda S. Abe Y. Aminoglycoside antibiotics. IX. 1-N-acyl derivatives of kanamycin A (amikacin analogs). Journal of Antibiotics. 27(11): 851-8, 1974.

(9) Davies J. Brzezinska M. Benveniste R. The problems of drug-resistant pathogenic bacteria. R factors: biochemical mechanisms of resistance to aminoglycoside antibiotics. Annals of the New York Academy of Sciences. 182:226-33, 1971.

(10) Perlin MH. Lerner SA Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli. Antimicrobial Agents & Chemotherapy. 16(5): 598-604, 1979.

(11) Cabana BE. Taggart JG. Comparative pharmacokinetics of BB-K8 and kanamycin in dogs and humans. Antimicrobial Agents & Chemotherapy. 3(4):478-83, 1973.

(12) Susan Budavari etal. Merck Research Laboratory. Merck Index 12th edition:425,619.

(13) Kaplan MA. Coppola WP. Nunning BC. Granatek AP. Pharmaceutical properties and stability of amikacin - part I. Current Therapeutic Research, Clinical & Experimental. 20(4): 352-8, 1976.

(14) Nunning BC. Granatek AP. Physical compatibility and chemical stability of amikacin sulfate in combination with non-antibiotic drugs in large-volume parenteral solutions - part IV. Current Therapeutic Research, Clinical & Experimental. 20(4):417-91, 1976.

(15)潘正安,中華人民共和國藥典-藥典注釋,第二版二部 1 版,化學工業出版社,1993.

(16)張博雅,中華藥典第四版,行政院衛生署藥物食品檢驗局叢書出版社,1995.

(17) Drasar FA. Farrell W. Maskell J. Williams JD. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods. British Medical Journal. 2(6047):1284-7, 1976.

(18)Price KE. Chisholm DR. Misiek M. Leitner F. Tsai YH. Microbiological evaluation of BB-K 8, a new semisynthetic aminoglycoside. Journal of Antibiotics. 25(12):709-31, 1972.

(19). Mitsuhashi S. Kawabe H. Iyobe S. Tanaka T. Inoue M. [Antibacterial activity of a new semisynthetic aminoglycoside antibiotic amikacin (BB-K8) (author's transl)]. [Japanese] Japanese Journal of Antibiotics. 27(2):189-92, 1974.

(20)Young LS. Hewitt WL. Activity of five aminoglycoside antibiotics in vitro against gram-negative bacilli and Staphylococcus aureus. Antimicrobial Agents & Chemotherapy. 4(6): 617-25, 1973.

(21) Jaime N.D. William A.R. Wilson and Gisvold's Textbook of organic Medicinal and Pharmaceutical Chemistry. J.B. Lippincott Company. Fourth Edition.1995.

(22) Wingard. Brody. Larner. Schwartz. Human Pharmacology, Mosby-Year Book.1991.

(23) Singh YN. Marshall IG. Harvey AL. Some effects of the aminoglycoside antibiotic amikacin on neuromuscular and autonomic transmission. British Journal of Anaesthesia. 50(2): 109-17, 1978.

(24) Philip D.H. Drug Interactions. Foruth Edition.

(25) Holt HA. Broughall JM. McCarthy M. Reeves DS. Interactions between aminoglycoside antibiotics and carbenicillin or ticarillin. Infection. 4(2): 107-9, 1976.

(26) Ueda Y. Uba F. Go K. Okamoto Y. Okubo H. [Fundamental and clinical studies on BB-K8 (amikacin), a new semisynthetic aminoglycoside antibiotic (author's transl)]. [Japanese] Japanese Journal of Antibiotics. 27(3): 354-65, 1974.

(27) Lerner SA. Seligsohn R. Matz GJ. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. American Journal of Medicine. 62(6):919-23, 1977.

(28) Smith CR. Maxwell RR. Edwards CQ. Rogers JF. Lietman PS. Nephrotoxicity induced by gentamicin and amikacin. Johns Hopkins Medical Journal. 142(3):85-90, 1978.

(29) Black RE. Lau WK. Weinstein RJ. Young LS. Hewitt WL. Ototoxicity of amikacin. Antimicrobial Agents & Chemotherapy. 9(6): 956-61, 1976.

(30) Reiffenstein JC. Holmes SW. Hottendorf GH. Bierwagen ME. Ototoxicity studies with BB-K8, a new semisynthetic aminoglycoside antibiotic. Journal of Antibiotics. 26(2): 94-100, 1973.

(31) St. Louis. A Wolters Kluwer Company. Drugs,Facts and Comparsions. 52th edition: 2376,2192 1998.

(32) Lanao JM. Pedraz JL. Navarro AS. Dominguez-Gil A. Influence of dose in the urinary excretion of amikacin. International Journal of Clinical Pharmacology, Therapy, & Toxicology. 22(10): 538-42, 1984.

(33) Leroy A. Humbert G. Oksenhendler G. Fillastre JP. Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients. Journal of Antimicrobial Chemotherapy. 2(4): 373-81, 1976.

(34) Kendall MJ. Wise R. Andrews JM. Bedford KA. A pharmacological study of UK-18,892 and amikacin. Journal of Antimicrobial Chemotherapy. 4(5):459-63, 1978.

(35) Yates RA. Mitchard M. Disposition studies with amikacin after rapid intravenous and intramuscular administration to human volunteers. Journal of Antimicrobial Chemotherapy. 4(4): 335-41, 1978.

(36) Daschner F. Reiss E. Engert J. Distribution of amikacin in serum, muscle, and fat in children after a single intramuscular injection. Antimicrobial Agents & Chemotherapy. 11(6):1081-3, 1977.

(37)Shah VP. Midha KK. Dighe S. McGilveray IJ. Skelly JP. Yacobi A. Layloff T. Viswanathan CT. Cook CE. McDowall RD. et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. European Journal of Drug Metabolism & Pharmacokinetics. 16(4): 249-55, 1991.

(38)Clarke JT. Libke RD. Regamey C. Kirby WM. Comparative pharmacokinetics of amikacin and kanamycin. Clinical Pharmacology & Therapeutics. 15(6): 610-6, 1974.

(39)Lanao JM. Dominguez-Gil A. Tabernero JM. De Castro S. Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function. International Journal of Clinical Pharmacology & Biopharmacy. 17(4): 171-5, 1979.

(40)Bodey GP. Valdivieso M. Feld R. Rodriguez V. Pharmacology of amikacin in humans. Antimicrobial Agents & Chemotherapy. 5(5): 508-12, 1974.

(41)Pfeffer M. Van Harken DR. Effect of dosing volume on intramuscular absorption rate of aminoglycosides. Journal of Pharmaceutical Sciences. 70(4):449-52, 1981.

(42)Sarubbi FA Jr. Hull JH. Amikacin serum concentrations: prediction of levels and dosage guidelines. Annals of Internal Medicine. 89(5 Pt 1):612-8, 1978.

(43) Wong LT. Beaubien AR. Pakuts AP. Determination of amikacin in microlitre quantities of biological fluids by high-performance liquid chromatography using 1-fluoro-2,4-dinitrobenzene derivatization. Journal of Chromatography. 231(1): 145-54, 1982.

(44) Barends DM. Blauw JS. Smits MH. Hulshoff A. Determination of amikacin in serum by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography. 276(2): 385-94, 1983.

(45) Papp EA. Knupp CA. Barbhaiya RH. High-performance liquid chromatographic assays for the quantification of amikacin in human plasma and urine. Journal of Chromatography. 574(1): 93-9, 1992.

(46) Wichert B. Schreier H. Derendorf H. Sensitive liquid chromatography assay for the determination of amikacin in human plasma. Journal of Pharmaceutical & Biomedical Analysis. 9(3): 251-4, 1991.

(47) Dandliker WB. Kelly RJ. Dandliker J. Farquahar J. Levin J. Fluorescence polarization immunoassay. Theory and experimental method. Immunochemistry. 10(4): 219-27, 1973.

(48) White LO. Holt HA. Reeves DS. MacGowan AP. Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net. Journal of Antimicrobial Chemotherapy. 39(3): 355-61, 1997.

(49) Zaninotto M. Secchiero S. Paleari CD. Burlina A. Performance of a fluorescence polarization immunoassay system evaluated by therapeutic monitoring of four drugs. Therapeutic Drug Monitoring. 14(4): 301-5, 1992.

(50) Jolley ME. Stroupe SD. Wang CH. Panas HN. Keegan CL. Schmidt RL. Schwenzer KS. Fluorescence polarization immunoassay. I. Monitoring aminoglycoside antibiotics in serum and plasma. Clinical Chemistry. 27(7): 1190-7, 1981.

(51) Fukuchi H. Yoshida M. Tsukiai S. Kitaura T. Konishi T. Comparison of enzyme immunoassay, radioimmunoassay, and microbiologic assay for amikacin in plasma. American Journal of Hospital Pharmacy. 41(4): 690-3, 1984.

(52) Provoost AP. Van Schalkwijk WP. Adejuyigbe O. Van Leeuwen WB. Wagenvoort JH. Determination of aminoglycosides in rat renal tissue by enzyme immunoassay. Antimicrobial Agents & Chemotherapy. 25(4): 497-8, 1984.

(53) Van der Bijl P. Lawrance JF. Uebel RA. Brits DA. Kotze TJ. Assay of amikacin by two methods and four instruments [letter]. Journal of Antimicrobial Chemotherapy. 26(6):860-2, 1990.

(54) Acred P. Hunter PA. Mizen L. Rolinson GN. -amino-p-hydroxybenzylpenicillin (BRL 2333), a new broad-spectrum semisynthetic penicillin: in vivo evaluation. Antimicrobial Agents & Chemotherapy. 10:416-22, 1970.

(55) Antimicrobial Agents & Chemotherapy. 10: 416-22, 1970. Brogden RN. Heel RC. Speight TM. Avery GS. Amoxycillin injectable: a review of its antibacterial spectrum, pharmacokinetics and therapeutic use. [Review] [74 refs] Drugs. 18(3):169-84, 1979.

(56) Sabto J. Carson P. Morgan T. Evaluation of amoxycillin--a new semisynthetic penicillin. Medical Journal of Australia. 2(11): 537-41, 1973.

(57) Westphal JF. Deslandes A. Brogard JM. Carbon C. Reappraisal of amoxycillin absorption kinetics. Journal of Antimicrobial Chemotherapy. 27(5):647-54, 1991.

(58) Kiyota K. Habu Y. Sugano Y. Inokuchi H. Mizuno S. Kimoto K. Kawai K. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial. Journal of Gastroenterology. 34 Suppl 11:76-9, 1999.

(59) Pieramico O. Zanetti MV. Innerhofer M. Malfertheiner P. Omeprazole-based dual and triple therapy for the treatment of Helicobacter pylori infection in peptic ulcer disease: a randomized trial. Helicobacter. 2(2):92-7, 1997.

(60) Jones GR. Calder MA. Froud WJ. Inglis JM. Marr FM. Stewart SM. Amoxycillin: pilot study of its use in pneumonia and chronic bronchitis. British Journal of Clinical Practice. 27(5): 161-4, 1973.

(61) Pankey GA. Clinical experience with amoxicillin in the treatment of skin infections. Journal of Infectious Diseases. 129(0):suppl:S202-6, 1974.

(62) Harding, J.W. Lees, Lorna J. Amoxycillin, a new broad-spectrum penicillin(Amoxycillin) in general practice. Practitioner 209:363, 1972.

(63) Cox CE. Amoxicillin therapy of urinary tract infections. Journal of Infectious Diseases. 129(0): suppl:S235-6, 1974.

(64) Handsfield HH. Clark H. Wallace JF. Holmes KK. Turck M. Amoxicillin, a new penicillin antibiotic. Antimicrobial Agents & Chemotherapy. 3(2):262-5, 1973.

(65) Sutherland. R. Rolinson, G.N.: α-Amino-p-hydroxy-benzylpenicillin (BRL 2333), a new semisynthetic penicillin: In vitro eualutation; in Antimicrobial Agents and Chemotherapy 411: 1970.

(66) Black JR. Long JM. Zwickl BE. Ray BS. Verdon MS. Wetherby S. Hook EW 3d. Handsfield HH. Multicenter randomized study of single-dose ofloxacin versus amoxicillin-probenecid for treatment of uncomplicated gonococcal infection. Antimicrobial Agents & Chemotherapy. 33(2):167-70, 1989.

(67) Shanson DC. McNabb R. Hajipieris P. The effect of probenecid on serum amoxycillin concentrations up to 18 hours after a single 3 g oral dose of amoxycillin: possible implications for preventing endocarditis. Journal of Antimicrobial Chemotherapy. 13(6):629-32, 1984.

(68) Karney WW. Turck M. Holmes KK. Comparative therapeutic and pharmacological evaluation of amoxicillin and ampicillin plus probenecid for the treatment of gonorrhea. Antimicrobial Agents & Chemotherapy. 5(2): 114-8, 1974.

(69) Munnich D. Bekesi S. Curing of typhoid carriers by cholecystectomy combined with amoxycillin plus Probenecid treatment. Chemotherapy. 25(6):362-6, 1979.

(70) Francioli P. Moreillon P. Glauser MP. Comparison of single doses of amoxicillin or of amoxicillin-gentamicin for the prevention of endocarditis caused by Streptococcus faecalis and by viridans streptococci. Journal of Infectious Diseases. 152(1):83-9, 1985.

(71) May FW. Darroch JN. Diarrhea as a side effect of amoxycillin therapy. Medical Jo urnal of Australia. 2(11):617-9, 1979.

(72) Mulroy R. Amoxycillin rash in infectious mononucleosis. British Medical Journal. 1(852):554, 1973.

(73) Eshelman FN. Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrobial Agents & Chemotherapy. 14(4):539-43, 1978.

(74) Brusch JL. Bergeron MG. Barza M. Weinstein L. An in vitro and pharmacological comparison of amoxicillin and ampicillin. American Journal of the Medical Sciences. 267(1): 41-8, 1974.

(75) Welling PG. Huang H. Koch PA. Craig WA. Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. Journal of Pharmaceutical Sciences. 66(4):549-52, 1977.

(76) Spyker DA. Rugloski RJ. Vann RL. O'Brien WM. Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration. Antimicrobial Agents & Chemotherapy. 11(1):132-41, 1977.

(77) Gordon C. Regamey C. Kirby WM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrobial Agents & Chemotherapy. 1(6):504-7, 1972.

(78) Cortvriendt WR. Verschoor JS. Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittel-Forschung. 37(8):977-9, 1987.

(79) Arancibia A. Guttmann J. Gonzalez G. Gonzalez C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrobial Agents & Chemotherapy. 17(2):199-202, 1980.

(80) Dalhoff A. Koeppe P. von Kobyletzki D. [Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration (author's transl)]. [German] Arzneimittel-Forschung. 31(7):1148-57, 1981.

(81) Miki, F. Absorption, excretion, distribution and distribution and metabolism of amoxycillin. Paper present at an International Symposium on amoxycillin, London,September.p.25, 1973.

(82) Cole M. Kenig MD. Hewitt VA. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrobial Agents & Chemotherapy. 3(4): 463-8, 1973.

(83)Bodey GP. Nance J. Amoxicillin: in vitro and pharmacological studies. Antimicrobial Agents & Chemotherapy. 1(4):358-62, 1972.

(84) Sjovall J. Magni L. Bergan T. Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrobial Agents & Chemotherapy. 13(1):90-6, 1978.

(85) Zarowny D. Ogilvie R. Tamblyn D. MacLeod C. Ruedy J. Pharmacokinetics of amoxicillin. Clinical Pharmacology & Therapeutics. 16(6):1045-51, 1974.

(86) Arancibia A. Icarte A. Gonzalez C. Morasso I. Dose-dependent bioavailability of amoxycillin. International Journal of Clinical Pharmacology, Therapy, & Toxicology. 26(6):300-3, 1988.

(87) Dalhoff A. Koeppe P. Comparative pharmacokinetic analysis of amoxycillin using open two and three-compartment models. European Journal of Clinical Pharmacology. 22(3):273-9, 1982.

(88) Martin C. Mallet MN. Sastre B. Viviand X. Martin A. De Micco P. Gouin F. Comparison of concentrations of two doses of clavulanic acid (200 and 400 milligrams) administered with amoxicillin (2,000 milligrams) in tissues of patients undergoing colorectal surgery. Antimicrobial Agents & Chemotherapy. 39(1):94-8, 1995.

(89) Foulstone M. Reading C. Assay of amoxicillin and clavulanic acid, the components of Augmentin, in biological fluids with high-performance liquid chromatography. Antimicrobial Agents & Chemotherapy. 22(5):753-62, 1982.

(90) Chulavatnatol S. Charles BG. High-performance liquid chromatographic determination of amoxicillin in urine using solid-phase, ion-pair extraction and ultraviolet detection. Journal of Chromatography. 615(1):91-6, 1993.

(91) Krauwinkel WJ. Volkers-Kamermans NJ. van Zijtveld J. Determination of amoxicillin in human plasma by high-performance liquid chromatography and solid phase extraction. Journal of Chromatography. 617(2):334-8, 1993.

(92) Molinaro M. Corona G. Fiorito V. Spreafico S. Bartoli AN. Zoia C. Bioavailability of two different oral formulations of amoxicillin in healthy subjects. Arzneimittel-Forschung. 47(12):1406-10, 1997.